Language
Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals

Blog

HomeHome / Blog / Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals
search

Jun 26, 2023

Cuyuna Rock Club agate and mineral show set May 13

Jun 24, 2023

FREMONT ANNOUNCES: Signs Agreement on Vardenis Property in Armenia; Acquires Historic Data from Dundee Precious Metals; Applies for Exploration License over Urasar Mineral District in Northern Armenia

Aug 02, 2023

Neem leaf powder (Azadirachta indica) mitigates oxidative stress and pathological alterations triggered by lead toxicity in Nile tilapia (Oreochromis niloticus)

Oct 09, 2023

Ginkgo Bioworks and Centrient Pharmaceuticals Announce Expansion of Partnership Following Success of Initial Project to Bring Sustainable Innovation to the Generic API Space

Oct 18, 2023

Univar Solutions Expands Specialty Pharmaceutical and Nutraceutical Ingredient Portfolios with Grace SYLOID® FP Silica for Majority of Europe

Send your inquiry
SUBMIT

Sep 28, 2023

Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals

GUIDANCE DOCUMENT The purpose of this guidance is to assist sponsors in the

GUIDANCE DOCUMENT

The purpose of this guidance is to assist sponsors in the nonclinical evaluation of the immunotoxic potential of pharmaceuticals. Immunotoxicity is, for the purposes of this guidance, defined as unintended immunosuppression or stimulation (including hypersensitivity), which can include adverse effects of exaggerated pharmacology of pharmaceuticals that are intended to act as immunomodulators. This guidance applies to drug products, including small molecule drugs and oligonucleotides, as well as certain biological products such as biotechnology-derived therapeutic proteins (referred to herein as biopharmaceuticals). For the purposes of this guidance, the term pharmaceutical will be used as a general term that encompasses all of these product types. Cell and gene therapies, adjuvanted vaccines, and blood products are not within the scope of this guidance.

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management Food and Drug Administration 5630 Fishers Lane, Rm 1061 Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-5607.

06/05/2023

Search for FDA Guidance Documents